Similarly, engineering of TRAMP-C2 mouse prostate cancer cells to secrete Grp170 profoundly enhanced tumor immunogenicity, indicated by increased levels of tumor-infiltrating CD8+ T cells, enhanced cytolytic activity, and improved control of distant tumors (104), suggesting that the induction or manipulation of large HSPs for secretion may help break immune tolerance to cancer cells. The gene discussed is CD8A; the disease is neoplasm.